Phenibut Research Overview (also known as Beta-phenyl-GABA, Fenibut, Phenigamma, Noofen, Anvifen)
Phenibut is a synthetic derivative of gamma-aminobutyric acid (GABA) that acts primarily as a GABA-B receptor agonist, with additional effects reported at higher exposures and through downstream dopaminergic systems. It has been investigated and used clinically in parts of Eastern Europe for anxiolytic, sedative, and vestibular indications, while anecdotal users have pursued relaxation, social ease, sleep, or perceived cognitive benefits; however, tolerance, dependence, severe withdrawal, and poisoning risks substantially limit its safety and clinical utility.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Phenibut?
Phenibut, also called beta-phenyl-GABA, is a synthetic analogue of gamma-aminobutyric acid (GABA). It was developed in the Soviet Union during the 1960s by modifying the GABA molecule with a phenyl ring. This structural change increases lipophilicity and allows a portion of the compound to cross the blood-brain barrier, unlike GABA itself, which has very limited penetration into the central nervous system. Phenibut has been described in Soviet and post-Soviet pharmacology literature as an anxiolytic and tranquilizing agent, and historical accounts state that it was included in medical supplies associated with Soviet cosmonaut programs because it was intended to reduce anxiety without necessarily causing the same degree of cognitive impairment as conventional sedatives.
Phenibut has been used as a prescription or regulated medicine in Russia and several Eastern European countries under names such as Noofen and Anvifen. It is not approved by the United States Food and Drug Administration as a medication or dietary supplement ingredient, and it is subject to regulatory restrictions and import controls in the United States. Its legal status differs across European jurisdictions, and the statement that it is generally unscheduled in the United States or European Union should not be interpreted as approval, safety, or uniform legality: national rules vary, products may be seized or refused entry, and commercial preparations can be mislabeled or contaminated. Online availability as a powder or capsule has contributed to nonmedical use, often under the nootropic label, despite limited high-quality clinical evidence and a substantial dependence liability.
Research Indications
Anxiolytic & Sedative Effects
Acute anxiety reduction
Phenibut is a GABA-related compound with GABA-B receptor activity; historical clinical literature describes tranquilizing and anxiolytic effects.
Sedation and sleepiness
Sedation is a common pharmacologic effect and adverse outcome, particularly at higher exposures or when combined with other depressants.
Cognition & Subjective Well-Being
Nootropic claims
Improved focus, sociability, and mood are commonly reported by users, but robust modern controlled human evidence for cognitive enhancement is limited.
Stress-related performance
Reduced anxiety may subjectively improve performance under stress; sedation, impaired coordination, and delayed reactions can offset this effect.
Dependence & Withdrawal Research
Tolerance with repeated exposure
Case reports and poison-center data indicate that frequent or escalating use can produce tolerance and compulsive redosing.
Withdrawal syndromes
Abrupt discontinuation after sustained use has been associated with anxiety, agitation, insomnia, hallucinations, autonomic symptoms, and in severe cases delirium or seizures.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Initial tolerance assessment | 250 mg | Single exposure; do not redose same day | Oral |
| Historical anxiolytic use | 250–500 mg | Occasional only; avoid consecutive days | Oral |
| Higher-exposure reports | 500–1,000 mg | Not a routine protocol; elevated adverse-effect risk | Oral |
| Discontinuation after regular use | No self-directed dose | Clinician-supervised tapering may be required | Oral |
Timing
Oral onset may be delayed for several hours and effects can persist into the next day. Delayed onset makes same-day redosing particularly hazardous. Avoid driving, alcohol, and other sedatives for the full period of impairment.
Peptide Interactions
Additive CNS and respiratory depression can markedly increase risks of blackouts, aspiration, coma, and death.
Combined sedative effects may suppress breathing and consciousness; overdose risk is substantially increased.
Additive impairment, amnesia, falls, and respiratory depression are possible. Do not combine without prescriber oversight.
Both have GABA-B-related activity. Combination may intensify sedation and complicate dependence or withdrawal management.
May produce additive dizziness, ataxia, and sedation. Extra caution is warranted in people with respiratory risk factors.
No major direct interaction is established, but stimulation can mask subjective sedation and encourage unsafe redosing or driving.
Reported Research Timeline
010–2 hours: effects may be absent or subtle; avoid assuming a dose failed and avoid redosing.
022–4 hours: reported onset commonly includes reduced tension, relaxation, drowsiness, or impaired coordination.
034–8 hours: peak subjective effects may occur; sedation, dizziness, nausea, and reduced reaction time are more likely at higher exposure.
048–18 hours: residual calming or sedation can continue; do not drive, operate machinery, or combine with CNS depressants.
051–3 days: fatigue, low mood, rebound anxiety, or sleep disruption may occur as effects resolve, especially after larger exposures.
06Days to weeks of repeated use (reported in cited studies): tolerance and dependence risk rise; abrupt cessation after sustained use can cause medically significant withdrawal.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Phenibut can cause substantial sedation, dizziness, impaired judgment, poor coordination, and memory impairment.
Do not drive, swim alone, climb, or operate machinery while affected or during the following day if residual impairment remains.
Avoid alcohol, opioids, benzodiazepines, sleep medicines, and other CNS depressants due to additive respiratory and consciousness risks.
Avoid frequent or consecutive-day use; tolerance, escalating doses, and dependence have been documented.
People who are pregnant, have respiratory disease, seizure disorders, substance-use disorder, or take psychoactive prescriptions should seek clinician guidance before exposure.
Seek Medical Attention If:
Breathing is slow, shallow, difficult, or accompanied by blue or gray lips.
There is inability to stay awake, loss of consciousness, severe confusion, or repeated vomiting.
Agitation, hallucinations, delirium, severe insomnia, tremor, or seizures occur after reducing or stopping regular use.
Chest pain, fainting, a serious fall, injury, or suspected mixed-substance overdose occurs.
Quality Indicators
Verified Marker
Batch-specific certificate of analysis
Request a recent COA tied to the exact lot number, with identity, purity, date, laboratory, and analytical method clearly stated.
Verified Marker
Independent HPLC or LC-MS identity testing
A credible report should identify phenibut and quantify purity using a suitable chromatographic method, preferably from an independent laboratory.
Verified Marker
Heavy-metal and microbiological screening
Prefer testing for lead, arsenic, cadmium, mercury, and relevant microbial contaminants, with reported limits and results.
Acceptable Range
Accurate capsule labeling and net content
Capsule strength, ingredient form, capsule count, and serving mass should be explicit; independent weight-uniformity data are preferable.
Quality Concern
Proprietary blends or unverifiable testing
Avoid products without lot-linked documentation, with implausibly high purity claims, unclear salt form, or no independent laboratory verification.
Research Citations
- Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug
Lapin, I., 2001, CNS Drug Reviews - Phenibut: A Novel Drug of Abuse and Potential for Overdose
Samokhvalov, A. V., et al., 2016, Journal of Medical Toxicology - Phenibut exposures and clinical effects reported to a regional poison center
McCabe, D. J., et al., 2018, Clinical Toxicology - Acute phenibut withdrawal: a comprehensive literature review and case report
Brunner, E., et al., 2018, CNS Drugs
Research Focus
GABA-B agonism, anxiety, sleep, cognitive enhancement, tolerance, withdrawal, nootropic
Frequently Asked Questions
What should researchers watch for with Phenibut?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Phenibut?
0–2 hours: effects may be absent or subtle; avoid assuming a dose failed and avoid redosing.
How is Phenibut typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →